Metabolism of Casodex in laboratory animals.

1. Casodex, a non-steroidal antiandrogen, was eliminated primarily in faeces by rat, mouse, rabbit and dog. Rat, mouse and rabbit eliminated 20-30% of a single oral dose (8-25 mg/kg) in urine; only 3-4% was excreted in urine by dog (2.5 mg/kg). Oral absorption was about 80% in rat, mouse, rabbit and dog. 2. Most of the dose was recovered in 48 h from rat, mouse and rabbit. In rat, < 1% of the dose was exhaled as 14CO2 and < 1% remained in the carcass after 7 days. Recovery from dog was incomplete in 4 days but consistent with the long plasma elimination half-life of 7-7.5 days. Casodex was eliminated from rat plasma with a half-life of 17-21 h. 3. Examination of urine indicated extensive metabolism of Casodex and showed a marked species difference. In rat, mouse and dog, Casodex was cleaved at the amide to yield a carboxylic acid and an aromatic amine which subsequently underwent ring hydroxylation with sulphate conjugation. In rabbit, the major urinary metabolite was Casodex glucuronide, conjugated on the tertiary hydroxyl. 4. The major component in faeces of all species was unchanged Casodex; some hydroxy-Casodex was also observed in rat faeces. Analysis of rat and dog bile indicated that Casodex and hydroxy-Casodex were eliminated in bile primarily as glucuronide conjugates.

[1]  R. Yates,et al.  Metabolism and enantioselective pharmacokinetics of Casodex in man. , 1993, Xenobiotica; the fate of foreign compounds in biological systems.

[2]  I. Cockshott,et al.  The pharmacokinetics of Casodex in laboratory animals. , 1991, Xenobiotica; the fate of foreign compounds in biological systems.

[3]  J. Lumley.  Essentials of Experimental Surgery , 1990 .

[4]  S. Freeman,et al.  A possible explanation for the peripheral selectivity of a novel non-steroidal pure antiandrogen, Casodex (ICI 176,334). , 1989, British Journal of Cancer.

[5]  B. Furr.  "Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies. , 1989, Hormone research.

[6]  H. Tucker,et al.  Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides. , 1988, Journal of medicinal chemistry.

[7]  H. Tucker,et al.  Resolution of the nonsteroidal antiandrogen 4'-cyano-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3'- (trifluoromethyl)-propionanilide and the determination of the absolute configuration of the active enantiomer. , 1988, Journal of medicinal chemistry.

[8]  J. Woodburn,et al.  ICI 176,334: a novel non-steroidal, peripherally-selective antiandrogen. , 1987, Progress in clinical and biological research.

[9]  K. Hoffmann,et al.  The metabolic disposition of the selective beta 1-adrenoceptor agonist prenalterol in mice, rats, dogs, and humans. , 1982, Drug metabolism and disposition: the biological fate of chemicals.

[10]  C. Filer,et al.  A novel technique for assessment of biliary secretion and enterohepatic circulation in the unrestrained conscious rat. , 1981, Xenobiotica; the fate of foreign compounds in biological systems.

[11]  W. G. Levine.  Biliary excretion of drugs and other xenobiotics. , 1978, Annual review of pharmacology and toxicology.

[12]  B. Katchen,et al.  Percutaneous penetration and metabolism of topical (14C)flutamide in men. , 1976, The Journal of investigative dermatology.

[13]  B. Katchen,et al.  Disposition of a New, Nonsteroid, Antiandrogen, α,α,α-Trifluoro-2-methyl-4′-nitro-m-propionotoluidide (Flutamide), in Men Following a single Oral 200 mg Dose , 1975 .

[14]  J. S. Fowler,et al.  A new cannula for collection or return of biological samples. , 1972, The British veterinary journal.

[15]  R. Smith,et al.  Excretion of Drugs in Bile , 1971 .